Véronique is a seasoned global executive with extensive experience in company building, value creation strategies, financing, BD and M&A. She has negotiated over 100 transactions throughout her career both on the buy-side and the sell-side in the field of pharmaceuticals, biosimilars, diagnostics, digital and consumer health. She helped reshape R&D pipelines, develop strategic options and raise capital. Through her work, Véronique enabled several medicines to reach patients (Yervoy®, Steglatro®, Truxima®, Herzuma®, Decapeptyl®, Cabozantinib®, and Sohonos®).
Véronique is currently a strategic advisor to several biotechs and foodtechs. Prior to her advisory roles, she was CBO & Head of Finance at Cedilla Therapeutics, a venture-backed series B biotech focused on precision oncology. At Cedilla, Véronique helped secure $25M in series B financing expansion, and an asset acquisition by Bayer of its CDK2 program. Prior to Cedilla, Véronique was SVP Global BD and Alliance Management at IPSEN. Prior to IPSEN, Veronique held various BD, M&A and Alliance Management roles of increasing responsibilities at Pfizer, Takeda, Teva, BMS and Monsanto.
Véronique currently also serves on the Board of Directors of Persephone Biosciences Inc. She has past Board experience with Portal Instruments, Aviir and iCardiac.
She is an Executive Coach since 2018 for the MassNextGen program and since 2022 for the SpringBoard program, mentoring female CEOs with strategy, finance and BD.
Véronique holds a BS and a MS in Economics from Université Libre de Bruxelles (ULB), Belgium.
